What's in Keith G. LeBlanc, Jr, MD's pipeline?

Keith G. LeBlanc, Jr, MD has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Keith G. LeBlanc, Jr, MD's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/keith-g-leblanc-jr-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Keith G. LeBlanc, Jr, MD — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Keith G. LeBlanc, Jr, MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Timolol 0.25% Ophthalmic Solution	Timolol 0.25% Ophthalmic Solution	marketed	Beta-adrenergic antagonist (non-selective beta-blocker)	Beta-1 and beta-2 adrenergic receptors	Ophthalmology

Therapeutic area mix

Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Keith G. LeBlanc, Jr, MD:

Cite this brief

Drug Landscape (2026). Keith G. LeBlanc, Jr, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/keith-g-leblanc-jr-md. Accessed 2026-05-17.